

Pembrolizumab PEARLS/KEYNOTE-091

### PRELIMINARY SCORE

**CURATIVE**



**NON-CURATIVE**



### ADJUSTMENTS

**Quality of life**



**Serious and disabling adverse effects**



**Other adjustments**



Pembrolizumab PEARLS/KEYNOTE-091

### FINAL SCORE

**CURATIVE**




Overall Survival / Disease-Free Survival / Pathological Complete Response

**NON-CURATIVE**




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

**INFORMATION**

Tumour type: Thoracic Malignancies  
 Therapeutic Indication: Adjuvant treatment of adults with non-small cell lung carcinoma who are at high risk of recurrence following complete resection and platinum-based chemotherapy  
 Experimental Arm: Pembrolizumab  
 Control Arm: Placebo

